9 May 2014

The National Institute for Health and Care Excellence (NICE) has released its final guidance on using advanced prostate cancer drug enzalutamide in England and Wales, approving it for use on the NHS for men who have already been treated with the chemotherapy drug docetaxel – and removing a restriction around its use after abiraterone.

The decision comes after heavy campaigning by us and thousands of our supporters to remove the restriction around abiraterone, which would have meant that some men who would benefit from enzalutamide might not be able to get hold of it.

Men United against NICE

Over 13,500 people signed our petition to get the National Institute for Health and Care Excellence (NICE) to remove the caveats around their approval of enzalutamide for use on the NHS – a clear example of Men United in action.

Read more about this decision and see our campaign in action. 

The decision

Enzalutamide, a life-extending drug for treatment of advanced prostate cancer, will be made available on the NHS in England and Wales without a blanket restriction against men who’ve previously been treated with abiraterone.

NICE have agreed that there isn’t enough clinical evidence to impose such a restriction, but they’ve also said that there isn’t yet enough clinical evidence to recommend its use in this context either. This means that the use of enzalutamide after abiraterone isn’t covered by the final guidance.

What does this mean in practice?

We can’t say for sure immediately.  

We expect that since NICE have stated that there is no clinical reason not to prescribe enzalutamide after abiraterone, all men who need it should now be able to receive this drug. But we need to make sure that this is the case before we know whether we need to continue to fight for all men who need it to have access to it.

Our priority now is making sure every man who needs this drug can access it.

We need to hear from you

Were you waiting for this decision? Do you now have access to enzalutamide or not? Hearing form you will help us decide if we still have work to do, so let us know 

comments powered by Disqus